TRCT
RNAZ icon

Tower Research Capital (TRC)’s TransCode Therapeutics RNAZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2K Buy
677
+449
+197% +$3.05K ﹤0.01% 4423
2026
Q1 		$1.96K Sell
228
-659
-74% -$6.15K ﹤0.01% 4570
2025
Q4 		$6.06K Buy
887
+745
+525% +$7.64K ﹤0.01% 4080
2025
Q3 		$1.53K Sell
142
-260
-65% -$2.71K ﹤0.01% 4773
2025
Q2 		$3.14K Buy
402
+347
+631% +$3.21K ﹤0.01% 4545
2025
Q1 		$756 Buy
55
+22
+67% +$2.82K ﹤0.01% 4835
2024
Q4 		$3.12K Buy
33
+26
+371% +$9.61K ﹤0.01% 4711
2024
Q3 		$3.7K Sell
7
-2
-22% -$809 ﹤0.01% 4793
2024
Q2 		$7.91K Buy
9
+4
+80% +$3.56K ﹤0.01% 4410
2024
Q1 		$3.37K Buy
+5
New +$6.99K ﹤0.01% 4874
2023
Q4 		– Hold
0
– – – 5478
2023
Q3 		– Hold
0
– – – 5119
2023
Q2 		– Hold
0
– – – 3938
2023
Q1 		– Hold
0
– – – 5392
2022
Q4 		– Hold
0
– – – 5054
2022
Q3 		– Hold
0
– – – 5041
2022
Q2 		– Hold
0
– – – 4701
2022
Q1 		– Hold
0
– – – 4919
2021
Q4 		– Hold
0
– – – 5061
2021
Q3 		– Hold
0
– – – 4995

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Tower Research Capital (TRC)'s RNAZ Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its TransCode Therapeutics (RNAZ) stake by 197% in Q2 2026, buying an estimated $3.05K and bringing the position to 677 shares worth $4.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4423.

Tower Research Capital (TRC) first reported a position in RNAZ in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.91K in Q2 2024. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Tower Research Capital (TRC) held 677 shares of TransCode Therapeutics worth $4.2K as of Q2 2026.
  • Tower Research Capital (TRC) bought 449 TransCode Therapeutics shares in Q2 2026, an estimated $3.05K.
  • TransCode Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4423 holding.
  • Tower Research Capital (TRC) first reported a position in TransCode Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s TransCode Therapeutics position peaked at $7.91K in Q2 2024.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.